AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1501561 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 2,500 m in a hypobaric chamber at 70% altitude VO2max (N = 14)
Number of subjects: 21
Study 6563903 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.1 mg/kg in 15 ml of normal saline
Number of subjects: 174
Study 6563903 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 0.1 mg/kg and normal saline 15 ml epidurally
Number of subjects: 174
Study 6563903 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 15 ml epidurally and normal saline 0.01 ml/kg intramuscularly
Number of subjects: 174
Study 31930890 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy group (tongdu tiaoshen moxibustion + rehabilitation training)
Number of subjects: 60
Study 31930890 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation group (rehabilitation training only)
Number of subjects: 60
Study 31930890 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy group
Number of subjects: 60
Study 31930890 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 60
Study 30123942 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (0.01-5 mg/kg IV, 0.25-1 mg/kg SC, 18 mg SC, 90 mg SC, 180 mg SC for psoriasis; 200 or 600 mg IV every 4 weeks followed by 180 mg SC every 8 weeks for Crohn's disease)
Number of subjects: 272
Study 30120772 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 3146
Study 30120772 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 3146
Study 30120772 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or ezetimibe)
Number of subjects: 3146
Study 27487251 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) with wearable sensor
Number of subjects: 0
Study 27487251 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS)
Number of subjects: 0
Study 24220044 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in methods of preventing childhood obesity (5-day workshop on dietary and physical activity interventions, and motivational interviewing)
Number of subjects: 60
Study 24220044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 22435769 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing therapy
Number of subjects: 6
Study 22435769 — intervention group
Group type: COMPARATOR
Intervention: Face to face therapy
Number of subjects: 6
Study 19328269 — intervention group
Group type: COMPARATOR
Intervention: Frequent cyclers
Number of subjects: 121
Study 19328269 — intervention group
Group type: COMPARATOR
Intervention: Moderate cyclers
Number of subjects: 121
Study 17145205 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50mg tablet
Number of subjects: 25
Study 16874150 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) training for 6 weeks (n=16)
Number of subjects: 24
Study 16874150 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 24
Study 12522748 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine with or without intranasal live‐attenuated, cold‐adapted influenza vaccine
Number of subjects: 2215
Study 10669155 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 56
Study 10669155 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 56
Study 8844501 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous injections of inhalant allergens at the maximum intradermally tolerated dose (MITD)
Number of subjects: 36
Study 1477693 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and alfentanil
Number of subjects: 43
Study 1477693 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia with isoflurane and alfentanil
Number of subjects: 43
Study 6700813 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 26
Study 6700813 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 26
Study 31037721 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming/water mattress (WarmTouch® and Norm‐O‐Temp®)
Number of subjects: 35
Study 31037721 — intervention group
Group type: COMPARATOR
Intervention: Conductive fabric warming (HotDog® electric blanket and mattress)
Number of subjects: 35
Study 29350831 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended right lobe grafts (ERG)
Number of subjects: 86
Study 29350831 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified right lobe grafts (MRG)
Number of subjects: 86
Study 27576515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (150 min/week)
Number of subjects: 129
Study 27576515 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive exercise (300 min/week)
Number of subjects: 129
Study 27576515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 24421901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir administered 2 doses/week for 6 weeks
Number of subjects: 24
Study 24421901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir administered 4 doses/week for 6 weeks
Number of subjects: 24
Study 24421901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir administered 7 doses/week for 6 weeks
Number of subjects: 24
Study 23032981 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS treatment
Number of subjects: 144
Study 23032981 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 144
Study 20447871 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 325
Study 20447871 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 325
Study 18569557 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially detrained group (50% of previous training duration)
Number of subjects: 16
Study 18569557 — intervention group
Group type: COMPARATOR
Intervention: Totally detrained group (no training)
Number of subjects: 16
Study 16052841 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg twice/day
Number of subjects: 146
Study 16052841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 12632885 — intervention group
Group type: EXPERIMENTAL
Intervention: V4R lead (Group V4R) instead of V1
Number of subjects: 100
Study 12632885 — intervention group
Group type: COMPARATOR
Intervention: Standard 12-lead ECG (Group V1)
Number of subjects: 100
Study 12632885 — intervention group
Group type: EXPERIMENTAL
Intervention: V4R lead (Group V4R)
Number of subjects: 100
Study 10365650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine + Sodium Valproate (n = 15)
Number of subjects: 21
Study 10365650 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (n = 22)
Number of subjects: 21
Study 10365650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (200-400 mg/d) before and after Sodium Valproate (900-1200 mg/d) for 4 weeks (n = 6)
Number of subjects: 21
Study 8523990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bilateral rapidly progressive SNHL
Number of subjects: 279
Study 8523990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Menière's disease
Number of subjects: 279
Study 8523990 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched patients with no hearing complaints)
Number of subjects: 279
Study 1911013 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.01 mg kg‐1
Number of subjects: 20
Study 1911013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flumazenil)
Number of subjects: 20
Study 6117682 — intervention group
Group type: EXPERIMENTAL
Intervention: Live influenza vaccine
Number of subjects: 36
Study 6117682 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated surface‐antigen influenza vaccine
Number of subjects: 36
Study 6117682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 36
Study 29884593 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF-ATRA
Number of subjects: 109
Study 29884593 — intervention group
Group type: COMPARATOR
Intervention: arsenic trioxide-ATRA
Number of subjects: 109
Study 28829884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Prednisolone (20 mg tablets, 2 tablets once daily for 5 days)
Number of subjects: 401
Study 28829884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo, 2 tablets once daily for 5 days)
Number of subjects: 401
Study 28829884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Prednisolone
Number of subjects: 401
Study 28829884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 26609161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 172
Study 26609161 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 172
Study 22878231 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) with cathodal stimulation, 20 minutes per day, 5 days per week, for 4 weeks, combined with conventional physical therapy
Number of subjects: 90
Study 22878231 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with conventional physical therapy
Number of subjects: 90
Study 21401253 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) procedure that paired images of snack foods with images of potential adverse health consequences
Number of subjects: 0
Study 21401253 — intervention group
Group type: COMPARATOR
Intervention: Control condition featuring images of snack foods alone
Number of subjects: 0
Study 18163509 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab every 6 weeks (continuous treatment)
Number of subjects: 247
Study 18163509 — intervention group
Group type: COMPARATOR
Intervention: Infliximab upon symptom recurrence (on-demand treatment)
Number of subjects: 247
Study 18163509 — intervention group
Group type: COMPARATOR
Intervention: Infliximab alone (on-demand treatment)
Number of subjects: 247
Study 18163509 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) in combination with infliximab (on-demand treatment)
Number of subjects: 247
Study 16385520 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 799
Study 16385520 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 799
Study 16385520 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 799
Study 14501633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen during the preoperative period
Number of subjects: 53
Study 14501633 — intervention group
Group type: COMPARATOR
Intervention: No preoperative analgesia
Number of subjects: 53
Study 11032921 — intervention group
Group type: EXPERIMENTAL
Intervention: BAP group (bleomycin, actinomycin-D, and cisplatin)
Number of subjects: 16
Study 11032921 — intervention group
Group type: COMPARATOR
Intervention: BEP group (bleomycin, etoposide, and cisplatin)
Number of subjects: 16
Study 8625627 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.43 IU recombinant growth hormone/kg body weight/day for 12 days
Number of subjects: 20
Study 8625627 — intervention group
Group type: COMPARATOR
Intervention: Saline for 12 days
Number of subjects: 20
Study 1425873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied methylprednisolone aceponate (MPA) at concentrations of 0.01% to 0.5%
Number of subjects: 20
Study 1425873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied methylprednisolone aceponate (MPA) at the highest dose
Number of subjects: 20
Study 6516045 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day surgery
Number of subjects: 350
Study 6516045 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 350
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF_a (experimental acidic sodium fluoride; 12500 ppmF-, pH 4.75)
Number of subjects: 30
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF_n (experimental neutral sodium fluoride; 12500 ppmF-, pH 7.0)
Number of subjects: 30
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: GB_a (acidic gel base; 0 ppmF-, pH 4.75)
Number of subjects: 30
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: GB_n (neutral gel base; 0 ppmF-, pH 7.0)
Number of subjects: 30
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF-NaF_a (experimental acidic amine/sodium fluoride; 12500 ppmF-, pH 4.75)
Number of subjects: 30
Study 31530840 — intervention group
Group type: EXPERIMENTAL
Intervention: EG_a (acidic amine/sodium fluoride; Elmex Geleé, CP-GABA GmbH; 12500 ppmF-, pH 4.75)
Number of subjects: 30
Study 31530840 — intervention group
Group type: COMPARATOR
Intervention: Control (no gel, without/with pellicle)
Number of subjects: 30
Study 29753732 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid for 8 weeks
Number of subjects: 19
Study 27716313 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and supportive supervision by paid Community Health Workers (CHWs)
Number of subjects: 82
Study 27716313 — intervention group
Group type: COMPARATOR
Intervention: Training alone
Number of subjects: 82
Study 25342100 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at five real acupoints (PC6, SP6, HT7, KI6, and BL62) used unilaterally in turn, treated three times during the first week.
Number of subjects: 38
Study 25342100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IDA) performed continuously on the subject's skin, stimulated at home every night.
Number of subjects: 38
Study 25342100 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at five sham acupoints over 1 cm away from each real acupoint.
Number of subjects: 38
Study 25342100 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture points provided by STRICTA.
Number of subjects: 38
Study 23659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen 2.5 or 5 mg/kg (DEX 1)
Number of subjects: 264
Study 23659181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen 3.5 or 7 mg/kg (DEX 2)
Number of subjects: 264
Study 23659181 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 5 or 10 mg/kg (control)
Number of subjects: 264
Study 20033066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 plasmid/lipopolymer complexes (phIL-12/PPC) at doses of 0.6, 3, 12 or 24 mg m(‐2) once every week for 4 weeks
Number of subjects: 13
Study 17949514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0
Study 17949514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16810572 — intervention group
Group type: EXPERIMENTAL
Intervention: LocaLisa mapping system
Number of subjects: 56
Study 16810572 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation technique
Number of subjects: 56
Study 12753337 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) administered as 10 MU QD or TIW for 4 weeks, followed by 5 MU QD or TIW for 20 weeks, and then by 3 MU QD or TIW for 24 weeks, in combination with ribavirin (1.0-1.2 g/day)
Number of subjects: 142
Study 11164321 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped information
Number of subjects: 30
Study 11164321 — intervention group
Group type: COMPARATOR
Intervention: Detailed written information
Number of subjects: 30
Study 9737555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 744
Study 9737555 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 744
Study 7930412 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 306
Study 7930412 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of valproate dose
Number of subjects: 306
Study 3265156 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intravenous methylprednisolone or oral prednisone) at a standard dose of 80 mg/day for 5 days or variable doses of 20-120 mg/day for 4-20 days, along with trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 33
Study 3265156 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intravenous methylprednisolone or oral prednisone)
Number of subjects: 33
Study 3265156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 33
Study 31061156 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS228 (multiple intravenous doses)
Number of subjects: 100
Study 31061156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple intravenous doses)
Number of subjects: 100
Study 31061156 — intervention group
Group type: EXPERIMENTAL
Intervention: LYS228 (single and multiple intravenous doses)
Number of subjects: 100
Study 27476066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand held dynamometry (HHD) with a portable stabilization device
Number of subjects: 15
Study 25932618 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 28
Study 25932618 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine + Constraint-Induced Aphasia Therapy (CIAT)
Number of subjects: 28
Study 25932618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 25932618 — intervention group
Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 28
Study 24280475 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughing Qigong Program (LQP)
Number of subjects: 67
Study 24280475 — intervention group
Group type: COMPARATOR
Intervention: Control (reading or doing homework)
Number of subjects: 67
Study 21691756 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes management programme (DMP) 'Therapie aktiv'
Number of subjects: 1489
Study 21691756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic medication (oral antidiabetics, insulin, or both)
Number of subjects: 1489
Study 21691756 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 1489
Study 21691756 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 1489
Study 21691756 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of care
Number of subjects: 1489
Study 19112586 — intervention group
Group type: EXPERIMENTAL
Intervention: Parthenolide-depleted Feverfew (PD-Feverfew)
Number of subjects: 0
Study 19112586 — intervention group
Group type: COMPARATOR
Intervention: Whole Feverfew
Number of subjects: 0
Study 16945893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) substructures (short random and continuous bidirectional fiber orientation) with a surface layer of PFC
Number of subjects: 8
Study 16945893 — intervention group
Group type: COMPARATOR
Intervention: Plain particulate filler composite (PFC)
Number of subjects: 8
Study 15265246 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 150-750 mg/day
Number of subjects: 620
Study 15265246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 11734864 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery plus WBRT
Number of subjects: 100
Study 11734864 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 100
Study 9402380 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine (12 mg) administered at 8:00 A.M. and 8:00 P.M. for ≤ 4 days after onset of symptoms
Number of subjects: 113
Study 8425662 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin infusion (3056 +/‐ 236 pM)
Number of subjects: 9
Study 8425662 — intervention group
Group type: COMPARATOR
Intervention: Low insulin infusion (486 +/‐ 33 pM)
Number of subjects: 9
Study 30612529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based physically active learning intervention (n = 52)
Number of subjects: 154
Study 30612529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based physically active learning intervention
Number of subjects: 154
Study 30612529 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 154
Study 30612529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Active pupils in the intervention
Number of subjects: 154
Study 30612529 — intervention group
Group type: EXPERIMENTAL
Intervention: Most Active pupils in the intervention
Number of subjects: 154
Study 30298673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antioxidant treatment (vitamins, antioxidants, and oligoelements) for six months
Number of subjects: 77
Study 30298673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 27323611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo Capsule (TC)
Number of subjects: 80
Study 27323611 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study 24777981 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g of milled flaxseed/d for 6 months)
Number of subjects: 0
Study 24777981 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid (from flaxseed)
Number of subjects: 0
Study 22456619 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(2), 2,000 IU daily for 6 weeks (arm A, control)
Number of subjects: 71
Study 22456619 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3), 2,000 IU daily for 6 weeks (arm B)
Number of subjects: 71
Study 22456619 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(2), 50,000 IU weekly for 6 weeks (arm C)
Number of subjects: 71
Study 22456619 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 71
Study 20600512 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mcg HBV vaccine with 250 mcg GM-CSF
Number of subjects: 48
Study 20600512 — intervention group
Group type: COMPARATOR
Intervention: 40 mcg HBV vaccine without GM-CSF (control)
Number of subjects: 48
Study 20600512 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF as an adjuvant
Number of subjects: 48
Study 20600512 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response based on CD4 count
Number of subjects: 48
Study 18241137 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart and Soul Physical Activity Program (HSPAP)
Number of subjects: 0